NO309455B1 - Filmbelagt tablett av paracetamol og domperidon - Google Patents

Filmbelagt tablett av paracetamol og domperidon Download PDF

Info

Publication number: NO309455B1
Authority: NO; Norway
Prior art keywords: tablet; domperidone; tablet according; paracetamol; tablets
Prior art date: 1994-02-28

Application number

NO962153A

Other languages

English (en)

Norwegian (no)

Other versions

NO962153L (no

NO962153D0 (no

Inventor

Gordon Prudhoe

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-28

Filing date

1996-05-28

Publication date

2001-02-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO309455(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-05-28 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

1996-05-28 Publication of NO962153D0 publication Critical patent/NO962153D0/no

1996-08-26 Publication of NO962153L publication Critical patent/NO962153L/no

2001-02-05 Publication of NO309455B1 publication Critical patent/NO309455B1/no

Links

229960001253 domperidone Drugs 0.000 title claims abstract description 30
FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 title claims abstract description 30
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 29
229960005489 paracetamol Drugs 0.000 title claims abstract description 28
239000007941 film coated tablet Substances 0.000 title abstract description 7
239000003826 tablet Substances 0.000 claims abstract description 52
238000000034 method Methods 0.000 claims abstract description 9
239000004480 active ingredient Substances 0.000 claims abstract description 8
239000000203 mixture Substances 0.000 claims description 17
239000007888 film coating Substances 0.000 claims description 15
238000009501 film coating Methods 0.000 claims description 15
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
239000002904 solvent Substances 0.000 claims description 11
229920002261 Corn starch Polymers 0.000 claims description 9
239000008120 corn starch Substances 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 9
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 8
239000000314 lubricant Substances 0.000 claims description 8
206010027599 migraine Diseases 0.000 claims description 8
208000019695 Migraine disease Diseases 0.000 claims description 7
229920000881 Modified starch Polymers 0.000 claims description 7
235000021355 Stearic acid Nutrition 0.000 claims description 7
239000008187 granular material Substances 0.000 claims description 7
235000019359 magnesium stearate Nutrition 0.000 claims description 7
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
239000008117 stearic acid Substances 0.000 claims description 7
OAUUYDZHCOULIO-BTJKTKAUSA-N domperidone maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.O=C1[NH2+]C2=CC=CC=C2N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2[NH2+]C1=O OAUUYDZHCOULIO-BTJKTKAUSA-N 0.000 claims description 6
229960004268 domperidone maleate Drugs 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
239000000454 talc Substances 0.000 claims description 6
229910052623 talc Inorganic materials 0.000 claims description 6
239000003979 granulating agent Substances 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
238000005550 wet granulation Methods 0.000 claims description 5
239000011230 binding agent Substances 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
238000007906 compression Methods 0.000 claims description 3
230000006835 compression Effects 0.000 claims description 3
229920001477 hydrophilic polymer Polymers 0.000 claims description 3
239000004014 plasticizer Substances 0.000 claims description 3
229940068918 polyethylene glycol 400 Drugs 0.000 claims description 3
239000001692 EU approved anti-caking agent Substances 0.000 claims description 2
239000002270 dispersing agent Substances 0.000 claims description 2
238000007580 dry-mixing Methods 0.000 claims description 2
-1 flow improvers Substances 0.000 claims description 2
239000006069 physical mixture Substances 0.000 claims description 2
239000000049 pigment Substances 0.000 claims description 2
239000003755 preservative agent Substances 0.000 claims description 2
239000000375 suspending agent Substances 0.000 claims description 2
230000009747 swallowing Effects 0.000 claims description 2
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 2
239000000730 antalgic agent Substances 0.000 abstract 1
239000002111 antiemetic agent Substances 0.000 abstract 1
229940125683 antiemetic agent Drugs 0.000 abstract 1
239000011248 coating agent Substances 0.000 description 8
238000000576 coating method Methods 0.000 description 8
229940099112 cornstarch Drugs 0.000 description 8
239000002552 dosage form Substances 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
235000012222 talc Nutrition 0.000 description 5
229920002472 Starch Polymers 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000000694 effects Effects 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000005461 lubrication Methods 0.000 description 3
239000008213 purified water Substances 0.000 description 3
239000004408 titanium dioxide Substances 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
244000061456 Solanum tuberosum Species 0.000 description 2
235000002595 Solanum tuberosum Nutrition 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
241000209140 Triticum Species 0.000 description 2
235000021307 Triticum Nutrition 0.000 description 2
240000008042 Zea mays Species 0.000 description 2
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
235000002017 Zea mays subsp mays Nutrition 0.000 description 2
235000013339 cereals Nutrition 0.000 description 2
235000005822 corn Nutrition 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000004800 polyvinyl chloride Substances 0.000 description 2
229920000915 polyvinyl chloride Polymers 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010009736 Protein Hydrolysates Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000005030 aluminium foil Substances 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000009172 bursting Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
238000005056 compaction Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003210 dopamine receptor blocking agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
230000005176 gastrointestinal motility Effects 0.000 description 1
208000001288 gastroparesis Diseases 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
239000008202 granule composition Substances 0.000 description 1
229920000591 gum Polymers 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
229920003125 hypromellose 2910 Polymers 0.000 description 1
229940031672 hypromellose 2910 Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229940063002 magnesium palmitate Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
230000008693 nausea Effects 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Dental Preparations (AREA)
Piezo-Electric Or Mechanical Vibrators, Or Delay Or Filter Circuits (AREA)

NO962153A 1994-02-28 1996-05-28 Filmbelagt tablett av paracetamol og domperidon NO309455B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP94200498		1994-02-28
PCT/EP1995/000719 WO1995022974A2 (fr)	1994-02-28	1995-02-27	Comprimes enrobes de paracetamol et de domperidone

Publications (3)

Publication Number	Publication Date
NO962153D0 NO962153D0 (no)	1996-05-28
NO962153L NO962153L (no)	1996-08-26
NO309455B1 true NO309455B1 (no)	2001-02-05

Family

ID=8216670

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO962153A NO309455B1 (no)	1994-02-28	1996-05-28	Filmbelagt tablett av paracetamol og domperidon

Country Status (29)

Country	Link
US (1)	US5814339A (fr)
EP (1)	EP0749308B1 (fr)
JP (1)	JP2931409B2 (fr)
KR (1)	KR100202154B1 (fr)
CN (1)	CN1084616C (fr)
AT (1)	ATE240102T1 (fr)
AU (1)	AU703242B2 (fr)
BR (1)	BR9506903A (fr)
CA (1)	CA2182004C (fr)
CY (1)	CY2383B1 (fr)
CZ (1)	CZ291999B6 (fr)
DE (1)	DE69530759T2 (fr)
DK (1)	DK0749308T3 (fr)
ES (1)	ES2199982T3 (fr)
FI (1)	FI117373B (fr)
HU (1)	HU228149B1 (fr)
IL (1)	IL112802A (fr)
MX (1)	MX9603690A (fr)
MY (1)	MY115433A (fr)
NO (1)	NO309455B1 (fr)
NZ (1)	NZ281236A (fr)
PL (1)	PL179080B1 (fr)
PT (1)	PT749308E (fr)
RU (1)	RU2153337C2 (fr)
SI (1)	SI0749308T1 (fr)
SK (1)	SK282506B6 (fr)
TW (1)	TW466119B (fr)
WO (1)	WO1995022974A2 (fr)
ZA (1)	ZA951616B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9710767D0 (en) *	1996-06-26	1997-07-23	On Ninh	Analgesic and anti-inflamatory compositions comprising domperidone and methods of using same
GB9702392D0 (en) *	1997-02-06	1997-03-26	Boots Co Plc	Therapeutic agents
GB9816899D0 (en)	1998-08-05	1998-09-30	Boots Co Plc	Therapeutic agents
US20030072731A1 (en) *	2001-05-15	2003-04-17	Cynthia Gulian	Dip coating compositions containing starch or dextrin
US20030070584A1 (en)	2001-05-15	2003-04-17	Cynthia Gulian	Dip coating compositions containing cellulose ethers
RU2266744C2 (ru) *	2001-06-21	2005-12-27	Duchesnay Ink.	Композиция быстрого начала действия
US8309118B2 (en)	2001-09-28	2012-11-13	Mcneil-Ppc, Inc.	Film forming compositions containing sucralose
RU2192848C1 (ru) *	2001-10-30	2002-11-20	Закрытое акционерное общество "ВЕРОФАРМ"	Противорвотное средство
US7429619B2 (en)	2002-08-02	2008-09-30	Mcneil Consumer Healthcare	Polyacrylic film forming compositions
RU2268047C2 (ru) *	2003-12-15	2006-01-20	Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское"	Лекарственная форма, обладающая противорвотным действием, и способ ее изготовления
GB2443793B (en) *	2006-04-05	2010-12-01	Reckitt Benckiser Healthcare	Product, method of manufacture and use
MX2009011577A (es) *	2007-04-26	2010-03-10	Craig A Aronchick	Composiciones y metodos para distribucion de domperidona a traves de la mucosa.
US20090060983A1 (en) *	2007-08-30	2009-03-05	Bunick Frank J	Method And Composition For Making An Orally Disintegrating Dosage Form
KR101560176B1 (ko)	2007-10-31	2015-10-14	맥네일-피피씨, 인코포레이티드	구강내 붕해성 투여 형태
US8858210B2 (en)	2009-09-24	2014-10-14	Mcneil-Ppc, Inc.	Manufacture of variable density dosage forms utilizing radiofrequency energy
US8343533B2 (en)	2009-09-24	2013-01-01	Mcneil-Ppc, Inc.	Manufacture of lozenge product with radiofrequency
US9233491B2 (en)	2012-05-01	2016-01-12	Johnson & Johnson Consumer Inc.	Machine for production of solid dosage forms
US9445971B2 (en)	2012-05-01	2016-09-20	Johnson & Johnson Consumer Inc.	Method of manufacturing solid dosage form
US9511028B2 (en)	2012-05-01	2016-12-06	Johnson & Johnson Consumer Inc.	Orally disintegrating tablet
FR2992218B1 (fr) *	2012-06-22	2015-01-23	Rivopharm Sa	Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
US9789066B2 (en)	2014-01-10	2017-10-17	Johnson & Johnson Consumer Inc.	Process for making tablet using radiofrequency and lossy coated particles
EP3411031B1 (fr) *	2016-02-04	2024-07-24	CinDome Pharma, Inc.	Compositions de dompéridone deutérée et méthodes pour la thérapie de troubles
US10493026B2 (en)	2017-03-20	2019-12-03	Johnson & Johnson Consumer Inc.	Process for making tablet using radiofrequency and lossy coated particles
KR20240125702A (ko)	2017-06-30	2024-08-19	신돔 파마, 인크.	중수소화 돔페리돈 조성물, 방법, 및 제조
US12478612B2 (en)	2017-06-30	2025-11-25	Cindome Pharma, Inc.	Deuterated domperidone compositions, methods, and preparation
CN110302169A (zh) *	2019-08-01	2019-10-08	张慧芬	一种滑膜衣片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU528098B2 (en) *	1978-11-16	1983-04-14	Beecham Group Plc	Analgesic tablet
CA2020018A1 (fr) *	1990-06-27	1991-12-28	Don L. Simmons	Methode et compose pour le traitement du complexe migraineux
MX9300110A (es) *	1992-01-13	1994-07-29	Gerhard Gergely	Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
CA2139638A1 (fr) *	1992-07-07	1994-01-20	Nancy M. Gray	Methodes d'utilisation de la (-) cisapride pour le traitement du reflux gastro-oesophagien et d'autres troubles
RU2068689C1 (ru) *	1992-09-24	1996-11-10	Товарищество с ограниченной ответственностью "Лекрон"	Способ получения таблеток парацетамола
TW272942B (fr) *	1993-02-10	1996-03-21	Takeda Pharm Industry Co Ltd
RU2034533C1 (ru) *	1993-02-25	1995-05-10	Химико-фармацевтическое акционерное общество открытого типа "Октябрь"	Анальгезирующее жаропонижающее лекарственное средство и способ его получения

1995
- 1995-02-24 TW TW084101709A patent/TW466119B/zh not_active IP Right Cessation
- 1995-02-27 BR BR9506903A patent/BR9506903A/pt not_active IP Right Cessation
- 1995-02-27 RU RU96111912/14A patent/RU2153337C2/ru active
- 1995-02-27 ES ES95909789T patent/ES2199982T3/es not_active Expired - Lifetime
- 1995-02-27 DK DK95909789T patent/DK0749308T3/da active
- 1995-02-27 NZ NZ281236A patent/NZ281236A/en not_active IP Right Cessation
- 1995-02-27 AT AT95909789T patent/ATE240102T1/de active
- 1995-02-27 EP EP95909789A patent/EP0749308B1/fr not_active Expired - Lifetime
- 1995-02-27 DE DE69530759T patent/DE69530759T2/de not_active Expired - Lifetime
- 1995-02-27 US US08/652,514 patent/US5814339A/en not_active Expired - Lifetime
- 1995-02-27 MX MX9603690A patent/MX9603690A/es unknown
- 1995-02-27 PL PL95314850A patent/PL179080B1/pl unknown
- 1995-02-27 SI SI9530668T patent/SI0749308T1/xx unknown
- 1995-02-27 ZA ZA951616A patent/ZA951616B/xx unknown
- 1995-02-27 PT PT95909789T patent/PT749308E/pt unknown
- 1995-02-27 JP JP7522147A patent/JP2931409B2/ja not_active Expired - Lifetime
- 1995-02-27 WO PCT/EP1995/000719 patent/WO1995022974A2/fr not_active Ceased
- 1995-02-27 SK SK1032-96A patent/SK282506B6/sk not_active IP Right Cessation
- 1995-02-27 CZ CZ19962255A patent/CZ291999B6/cs not_active IP Right Cessation
- 1995-02-27 HU HU9601384A patent/HU228149B1/hu unknown
- 1995-02-27 CN CN95191736A patent/CN1084616C/zh not_active Expired - Lifetime
- 1995-02-27 KR KR1019960702874A patent/KR100202154B1/ko not_active Expired - Lifetime
- 1995-02-27 MY MYPI95000497A patent/MY115433A/en unknown
- 1995-02-27 CA CA002182004A patent/CA2182004C/fr not_active Expired - Lifetime
- 1995-02-27 AU AU18123/95A patent/AU703242B2/en not_active Expired
- 1995-02-27 IL IL11280295A patent/IL112802A/xx not_active IP Right Cessation
1996
- 1996-05-22 FI FI962156A patent/FI117373B/fi not_active IP Right Cessation
- 1996-05-28 NO NO962153A patent/NO309455B1/no not_active IP Right Cessation
2003
- 2003-11-04 CY CY0300078A patent/CY2383B1/xx unknown

Also Published As

Publication number	Publication date
JP2931409B2 (ja)	1999-08-09
NO962153L (no)	1996-08-26
CN1084616C (zh)	2002-05-15
CA2182004C (fr)	2000-10-31
IL112802A (en)	1999-08-17
CN1141589A (zh)	1997-01-29
EP0749308A1 (fr)	1996-12-27
AU703242B2 (en)	1999-03-25
PL179080B1 (pl)	2000-07-31
FI117373B (fi)	2006-09-29
DE69530759T2 (de)	2004-03-18
IL112802A0 (en)	1995-05-26
WO1995022974A2 (fr)	1995-08-31
SI0749308T1 (en)	2003-10-31
HU228149B1 (en)	2012-12-28
FI962156A0 (fi)	1996-05-22
BR9506903A (pt)	1997-09-09
EP0749308B1 (fr)	2003-05-14
ES2199982T3 (es)	2004-03-01
CY2383B1 (en)	2004-06-04
CA2182004A1 (fr)	1995-08-31
SK103296A3 (en)	1997-03-05
MY115433A (en)	2003-06-30
WO1995022974A3 (fr)	1995-09-21
HK1010687A1 (en)	1999-06-25
PT749308E (pt)	2003-10-31
US5814339A (en)	1998-09-29
KR100202154B1 (ko)	1999-06-15
ATE240102T1 (de)	2003-05-15
JPH09500910A (ja)	1997-01-28
CZ225596A3 (en)	1996-11-13
SK282506B6 (sk)	2002-10-08
HUT74477A (en)	1996-12-30
RU2153337C2 (ru)	2000-07-27
AU1812395A (en)	1995-09-11
CZ291999B6 (cs)	2003-07-16
FI962156L (fi)	1996-06-04
HU9601384D0 (en)	1996-07-29
MX9603690A (es)	1997-06-28
ZA951616B (en)	1996-08-27
NO962153D0 (no)	1996-05-28
DK0749308T3 (da)	2003-09-01
TW466119B (en)	2001-12-01
NZ281236A (en)	2001-11-30
PL314850A1 (en)	1996-09-30
DE69530759D1 (de)	2003-06-18

Legal Events

Date	Code	Title	Description
2015-03-09	MK1K	Patent expired

Publication	Publication Date	Title
CA2182004C (fr)	2000-10-31	Comprimes enrobes de paracetamol et de domperidone
JP4744142B2 (ja)	2011-08-10	ラモトリギンを含む徐放性処方
JP5948648B2 (ja)	2016-07-06	安定化されたエペリゾンを含有する徐放性製剤
US20050158380A1 (en)	2005-07-21	Sustained release oral dosage forms of gabapentin
EP2448561A1 (fr)	2012-05-09	Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
KR100846945B1 (ko)	2008-07-17	파라세타몰을 포함하는 연하 정제
WO2014209087A1 (fr)	2014-12-31	Préparation composite pour gélule pharmaceutique comprenant du tadalafil et de la tamsulosine
WO2008029417A2 (fr)	2008-03-13	Formulation pharmaceutique employée dans la thérapie du vih
WO2009027786A2 (fr)	2009-03-05	Formes posologiques matricielles de varénicline
EP1512394A1 (fr)	2005-03-09	Composition universelle à libération controlée comprenant du chitosane
MXPA05002136A (es)	2005-06-03	Forma de dosificacion de liberacion controlada de nitrofurantoina.
CA2458776A1 (fr)	2003-03-06	Formulation a liberation controlee de clarithromycine ou de tinidazol
WO2006123213A1 (fr)	2006-11-23	Preparations a liberation modifiee de gliclazide
JPWO2003075919A1 (ja)	2005-06-30	塩酸ピルジカイニド含有錠剤（乾式）
CN111346066A (zh)	2020-06-30	含吡拉西坦的缓释制剂
AU2021275675B2 (en)	2024-11-14	Pharmaceutical composition
JP2021518424A (ja)	2021-08-02	様々な用量のレナリドミドの経口用錠剤組成物
EP1904037A1 (fr)	2008-04-02	Formulation a liberation prolongee de principes actifs presentant une solubilite dependante du ph
JP2002504107A (ja)	2002-02-05	（＋）−または（−）−シサプリドの即時放出性ｐＨ非依存的固形投薬剤形
HK1010687B (en)	2003-09-11	Film coated tablet of paracetamol and domperidone